OXiGENE Company Description
OXiGENE starves cancer to death. The company's lead drug candidate, Zybrestat, works by disrupting the functioning of blood vessels that deliver oxygen to tumors. The candidate is undergoing clinical trials as a treatment for one type of thyroid cancer. The company is also testing Zybrestat in other cancers, including lung, ovarian, and head and neck cancers. It is developing a topical form of the drug to treat age-related macular degeneration, an ocular disease that involves the abnormal formation of blood vessels. In addition, OXiGENE is working on a second-generation version of its oxygen-starving technology, and with Baylor University, is collaborating on some small molecule anti-cancer agents.
View the Comprehensive Company Description for OXiGENE
The Company Description provides a historical perspective of OXiGENE's organization from inception to current status.
Produced by Hoover's in-house editorial team, the Company Description tracks ownership transitions, company progress via mergers and acquisitions, major growth milestones, and strategic initiatives, to provide a holistic view of OXiGENE's evolution in the marketplace.
